Evidence map›Paper›PMID 36562402›Full record

ArticleCancer science2023

Circular RNA circ0104103 inhibits colorectal cancer progression through interactions with HuR and miR-373-5p.

Pei Tan, Huiling Sun, Mu Xu, Xiangxiang Liu, Jian Qin, Junjie Nie, Xiaodan Qin, Shukui Wang, Yuqin Pan

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. The Pivotal Role of LACTB in the Process of Cancer Development.International journal of molecular sciences · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Pei TanGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Huiling SunGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Mu XuDepartment of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Xiangxiang LiuGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Jian QinGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Junjie NieGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Xiaodan QinGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Shukui WangGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.ORCID https://orcid.org/0000-0001-6972-2587
Yuqin PanGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CNSoutheast University · CNJiangsu Cancer Hospital · CN

Funding

Elderly Health Research Project of Jiangsu Province LR2021017Jiangsu Provincial Key Research and Development Plan BE2019614Specialized Cohort Research Project of Nanjing Medical University NMUC2021013AThe National Nature Science Foundation of China 81972806
6 · The paper itself

Abstract

Emerging evidence has suggested that circular RNAs (circRNAs) have vital functions during the initiation and progression of various diseases. However, circRNA potential mechanisms in colorectal cancer (CRC) are largely unknown. Here, we sought to investigate the role and underlying regulatory mechanism of circ0104103 in CRC. circ0104103 was validated by quantitative RT-PCR (qRT-PCR) and Sanger sequencing. Gain- and loss-of-function assays in cell lines and mouse xenograft models were utilized to investigate the effects of circ0104103 in CRC. RNA pull-down assays, RNA immunoprecipitation assays, bioinformatics analyses, RNA FISH, and luciferase reporter assays were used to elucidate the potential mechanism of circ0104103 in CRC. We identified circ0104103, which is strongly downregulated in CRC tissues and cell lines. Functional studies revealed that circ0104103 inhibited CRC cell growth, migration, and invasion both in vitro and in vivo. Mechanistically, circ0104103 binds to HuR, a functional RNA-binding protein commonly expressed in CRC. HuR binds to the 3'UTR of LACTB mRNA to facilitate stabilization and increase its expression. Moreover, circ0104103 was verified as a competing endogenous RNA (ceRNA) via negative regulation of miR-373-5p to increase LACTB expression, resulting in inhibiting the occurrence and progression of CRC. Taken together, our study revealed that circ0104103 acts as a tumor suppressor and may be a novel biomarker and therapeutic target in CRC.

Indexed as

Colorectal NeoplasmsELAV-Like Protein 1MicroRNAsRNA, CircularAnimalsbeta-LactamasesCell Line, TumorCell ProliferationDisease Models, AnimalGene Expression Regulation, NeoplasticHumansMembrane ProteinsMiceMitochondrial ProteinsRNA Interferencebeta-LactamasesELAVL1 protein, humanELAV-Like Protein 1LACTB protein, humanMembrane ProteinsMicroRNAsMIRN373 microRNA, humanMitochondrial ProteinsRNA, CircularCircRNAcolorectal cancerHuRLACTBmicroRNA

Identifiers

PMID36562402
PMCPMC10067388
OpenAlexW4312114533

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.